# ARHGEF38

## Overview
ARHGEF38 is a gene that encodes the protein Rho guanine nucleotide exchange factor 38, which is involved in the regulation of Rho GTPases, a family of proteins that play a critical role in various cellular processes, including cytoskeletal dynamics, cell migration, and cell cycle progression. As a guanine nucleotide exchange factor (GEF), the protein facilitates the exchange of GDP for GTP on Rho GTPases, thereby activating them. This activation is crucial for the modulation of signaling pathways that govern cell morphology and motility. The ARHGEF38 gene has been studied for its involvement in cancer biology, particularly in prostate and lung cancers, where its expression levels have been linked to disease progression and prognosis (Sun2021Identification; Dhahbi2021LUAD). Additionally, alterations in ARHGEF38 have been associated with neurological conditions, highlighting its potential role in diverse pathological contexts (DíazCasado2020Analysis).

## Function


## Clinical Significance
ARHGEF38 has been implicated in several diseases due to its altered expression and genetic mutations. In prostate cancer, ARHGEF38 is significantly upregulated in cancerous tissues compared to normal tissues. Its higher expression levels are associated with worse overall survival in prostate cancer patients, suggesting its potential as a prognostic marker. Silencing ARHGEF38 in prostate cancer cell lines has been shown to suppress cell proliferation, migration, and invasion, indicating its role in the aggressive behavior of cancer cells (Sun2021Identification).

In the context of lung cancer, ARHGEF38 has been identified as a potential biomarker for distinguishing between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). It shows high diagnostic potential, with significant differences in expression levels between these cancer types (Dhahbi2021LUAD).

ARHGEF38 has also been studied in the GASH/Sal model of epilepsy, where a high-impact mutation in the gene affects protein interactions. Although not directly linked to epilepsy, alterations in ARHGEF38's methylation pattern have been associated with changes in signaling pathways related to neurological conditions, suggesting a broader role in neurological disorders (DíazCasado2020Analysis).


## References


[1. (Sun2021Identification) Zhuolun Sun, Yunhua Mao, Xu Zhang, Shuo Lu, Hua Wang, Chi Zhang, Chutian Xiao, Yinghao Cao, Yunhao Qing, Yu Wang, and Ke Li. Identification of arhgef38, neto2, golm1, and sapcd2 associated with prostate cancer progression by bioinformatic analysis and experimental validation. Frontiers in Cell and Developmental Biology, September 2021. URL: http://dx.doi.org/10.3389/fcell.2021.718638, doi:10.3389/fcell.2021.718638. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.718638)

[2. (DíazCasado2020Analysis) Elena Díaz-Casado, Ricardo Gómez-Nieto, José M. de Pereda, Luis J. Muñoz, María Jara-Acevedo, and Dolores E. López. Analysis of gene variants in the gash/sal model of epilepsy. PLOS ONE, 15(3):e0229953, March 2020. URL: http://dx.doi.org/10.1371/journal.pone.0229953, doi:10.1371/journal.pone.0229953. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0229953)

3. (Dhahbi2021LUAD) LUAD And LUSC Cancer Classification, Biomarker Identification, and Pathway Analysis Using Overlapping Feature Selection Methods. This article has 0 citations.